Pharmacoeconomic report : (KYE Pharmaceuticals): Indication: Stable Angina Pectoris, Adults: Ranolazine (Corzyna) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Insurance, Health, Reimbursement.

Physical Description:

1 online resource (35 pages)

Edition:

Version: Final (with redactions).

Other Title:

Pharmacoeconomic report

Place of Publication:

Ottawa, Ontario : Canadian Agency for Drugs and Technologies in Health, 2021.

Summary:

CADTH undertook reanalyses to address limitations in the sponsor's submission, including using an appropriate value for the rate of ranolazine response, correcting health-state resource costs, adopting a wider range of possible utility values, and extending the analysis to a lifetime horizon. CADTH was unable to address several important limitations associated with the model structure. Notably, the sponsor's model considered only the frequency of angina symptoms and did not consider symptom severity, a clinically relevant marker of treatment response. It is unclear whether the small incremental quality-adjusted life-year (QALY) gains would provide meaningful benefit to patients. Given these limitations, the uncertainty regarding the strength of the comparative effectiveness evidence, and the generalizability of the pivotal trial evidence to a Canadian population, the comparative clinical effectiveness of ranolazine is highly uncertain. The cost-effectiveness of ranolazine is therefore also uncertain.

Contents:

Abbreviations

Executive Summary

Conclusions

Stakeholder Input Relevant to the Economic Review

Economic Review

Economic Evaluation

Issues for Consideration

Overall Conclusions

Appendix 1. Cost Comparison Tables

Appendix 2. Submission Quality

Appendix 3. Additional Information on the Submitted Economic Evaluation

Appendix 4. Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation

Appendix 5. Submitted Business Impact Analysis and CADTH Appraisal

References.

Notes:

Description based on online resource; title from PDF title page (Canadian Agency for Drugs and Technologies in Health, viewed April 20, 2023).